Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed + gefitinib vs gefitinib in EGFR-mutant stage IV non-squamous NSCLC (Phase 2, Japan)
jRCT1080221763Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Non-small cell lung cancer (NS-NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Gefitinib + pemetrexed with Gefitinib monotherapy (2 arms).
02
Drugs
gefitinibpemetrexed
03
Conditions
Non-small cell lung cancer (NS-NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT1080221763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080221763.